A focus on PD-L1 in human melanoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23251000.
- Also identified by DOI 10.1158/1078-0432.CCR-12-3312.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment of metastatic melanoma with inhibitors of the BRAF V600 oncogene in melanoma has been limited by the development of resistance. Combining the BRAF inhibitors with immunotherapy may prolong the response, but will acquisition of resistance to BRAF inhibitors also make melanoma cells resistant to immunotherapy?
Medical subject headings
- B7-H1 Antigen
- Drug Resistance, Neoplasm
- Melanoma
- Mitogen-Activated Protein Kinase Kinases
- Phosphatidylinositol 3-Kinases
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins B-raf